Adamas Pharmaceuticals, Inc. announced that on December 7, 2015, Jeffrey Knapp, Chief Operating Officer, resigned effective January 29, 2016, for personal reasons. John MacPhee, a member of board of directors, will provide commercial advisory oversight on an interim basis until a Chief Commercial Officer is named.
Adamas Pharmaceuticals, Inc.
Equities
ADMS
US00548A1060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+47.84% | 56.87B | |
+37.15% | 39.72B | |
-6.17% | 39.27B | |
-6.90% | 28.73B | |
+13.79% | 26.21B | |
-16.42% | 19.79B | |
+32.47% | 12.28B | |
+28.23% | 12.23B | |
+0.62% | 12.12B |